cbdMD Inc (YCBD) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is deteriorating, there are no positive trading signals, and technical indicators suggest the stock is overbought. Additionally, there are no significant positive catalysts or recent news to support a bullish outlook.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is at 86.913, which signals the stock is overbought. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at 1.145 and 1.291, while support levels are at 0.675 and 0.53. The pre-market price of 0.9471 is down -6.23%, indicating bearish sentiment in the short term.
NULL identified. No recent news or significant positive developments.
The pre-market price is down -6.23%, financial performance is deteriorating significantly, and the stock is overbought based on RSI.
In Q1 2026, revenue dropped by -1.89% YoY to $5,016,904. Net income declined by -67.06% YoY to -$324,602. EPS fell by -97.69% YoY to -0.04. Gross margin decreased by -9.48% YoY to 54.93%. These metrics indicate a significant decline in financial health.
No analyst rating or price target changes available.